ArticleSurgical case reports2026
Successful Combination Immunotherapy for Postoperative Recurrence of Esophageal Cancer Following Prior Immune Checkpoint Inhibitor Treatment: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEsophageal squamous cell carcinoma (ESCC) remains an extremely aggressive malignancy with a poor prognosis, particularly among patients with distant metastases. Although systemic chemotherapy is the standard of care for patients with stage IV disease, conversion surgery has emerged as a promising treatment strategy for selected patients who respond favorably to systemic therapy. The introduction of immune checkpoint inhibitors (ICIs) has increased the therapeutic opportunities. However, the optimal management of postoperative recurrence after ICI-based conversion surgery remains unclear. Here, we report a case of postoperative recurrent ESCC after ICI-based conversion surgery in which long-term disease control was achieved through sequential multidisciplinary treatment, including chemoradiotherapy and subsequent dual immune checkpoint blockade. CASE PRESENTATION: A 68-year-old woman was diagnosed with stage IVB ESCC (cT3N2M1b) with para-aortic lymph node metastasis. The patient received 3 cycles of pembrolizumab combined with cisplatin and 5-fluorouracil (FP), which resulted in marked tumor regression. She underwent robot-assisted thoracoscopic subtotal esophagectomy with para-aortic lymphadenectomy; an R0 resection was achieved. The pathological diagnosis was squamous cell carcinoma with grade 2b tumor regression. Postoperative adjuvant therapy with nivolumab was initiated. Five months after surgery, locoregional recurrence occurred, and the patient was treated with chemoradiotherapy using docetaxel, followed by combination immunotherapy with nivolumab and ipilimumab. Remarkable regression of the recurrent lesions was achieved, and the patient has remained disease-controlled for 22 months postoperatively without further treatment.
conclusionsDual immune checkpoint blockade with nivolumab and ipilimumab may represent a potential therapeutic option for patients with recurrent ESCC following ICI treatment. This case underscores the importance of individualized treatment strategies and the evolving role of immunotherapy in the multidisciplinary management of patients with advanced esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.